All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
POLARIX subgroup analysis: Pola-R-CHP for older patients aged ≥60 years with untreated DLBCL
Bookmark this article
|
Polatuzumab vedotin (Pola) is an anti-CD79b ADC that was approved in 2023 by the FDA in combination with rituximab (R)-CHP for the treatment of patients with untreated DLBCL based on results from the phase III POLARIX trial (NCT03274492).1 The Lymphoma Hub has previously covered the primary results and other analyses from the POLARIX trial. Results from a further subgroup analysis of this trial, focusing on older patients with previously untreated DLBCL aged ≥60 years (Pola-R-CHP, n = 311; R-CHOP, n = 318) were published in Blood Advances by Hu et al.1 The endpoints included PFS, OS, EFS, CRR, DFS, and safety.1 |
| Key learnings |
| Pola-R-CHP improved PFS in patients aged ≥60 years and across all age subgroups analyzed. The greatest benefit was in patients aged ≥70 years (HR, 0.63; 95% CI, 0.41–0.96), for whom the risk of disease progression, relapse, or death was reduced by 37% compared with R-CHOP. |
| In patients with an IPI score of 3–5, a PFS benefit was observed with Pola-R-CHP vs R-CHOP (2-year PFS difference, 13% in patients aged ≥70 years). In patients aged ≥60 years, OS was similar for Pola-R-CHP vs R-CHOP (HR, 0.99; 95% CI, 0.67–1.47). |
| Safety profiles were similar for Pola-R-CHP vs R-CHOP, including Grade 3–4 AEs (62.7% vs 61.5%), Grade 3–5 infections (15.0% vs 12.9%), and Grade 5 AEs (3.6% vs 3.2%). A higher rate of Grade 3–4 febrile neutropenia (16.3% vs 7.6%) was observed with Pola-R-CHP vs R-CHOP, highlighting the importance of G-CSF prophylaxis in this population. |
| Consistent with the POLARIX overall treatment population, Pola-R-CHP showed a favorable benefit-risk profile for patients aged ≥60 years with previously untreated DLBCL, suggesting that elderly patients can benefit from treatment with Pola-R-CHP with manageable toxicities. |
Abbreviations: ADC, antibody−drug conjugate; AE, adverse event; CHOP, cyclophosphamide-doxorubicin-vincristine-prednisone; CHP, cyclophosphamide-doxorubicin-prednisone; CI, confidence interval; CRR, complete response rate; DFS, disease-free survival; DLBCL, diffuse large B-cell lymphoma; EFS, event-free survival; FDA, U.S. Food and Drug Administration; G-CSF, granulocyte-colony stimulating factor; HR, hazard ratio; IPI, International Prognostic Index; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; Pola, polatuzumab vedotin; R, rituximab.
- Hu NL, Reagan PM, Shen LH, et al. Subgroup analysis of elderly patients (≥60 years) with diffuse large B-cell lymphoma in the phase 3 POLARIX study. Blood Adv. 2025. Online ahead of print. DOI: 10.1182/bloodadvances.2024014707
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
2 votes - 2 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox